Summit Therapeutics shares climbed sharply in morning trading after partner Akeso Inc. disclosed that the Phase III HARMONi-2 study met its prespecified interim overall survival (OS) key secondary endpoint. According to Akeso, ivonescimab given as monotherapy produced a statistically significant survival advantage compared with pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1.
The China-based HARMONi-2 trial enrolled 398 patients and had previously shown a meaningful benefit in progression-free survival. The new OS readout is being viewed as a reinforcement of ivonescimab's potential to be a best-in-class treatment within a competitive oncology indication.
Market reaction was immediate. The stock opened at $15.52 and pushed toward a session high of $16.32 during the morning, reflecting an intraday gain of roughly 11.6%. Those levels sit well above the company's 52-week low of $12.07, though considerably below the 52-week high of $29.23.
Analysts have parsed the data with some divergence of tone. H.C. Wainwright reiterated a Neutral rating on the shares and did not assign a price target, explicitly citing caution tied to the trial's China-only scope. Cantor Fitzgerald, by contrast, kept an Overweight rating. The broader sell-side picture remains skewed toward positive views, with ten buy ratings, seven holds and no sell recommendations noted among coverage.
Adding to the market's focus on these results is an approaching regulatory timeline: an FDA review date for the lung cancer indication is scheduled for mid-November. That calendar point increases the significance of successive positive data readouts as investors and analysts reassess the asset's regulatory and commercial prospects.
The wider market backdrop was constructive on the day, reinforcing the biotech-specific catalyst: the S&P 500 advanced about 0.5%, the Dow Jones Industrial Average rose roughly 0.8% and the Nasdaq gained approximately 0.6%. That risk-on tone helped amplify investor interest in Summit Therapeutics during the session.
In sum, the combination of a landmark interim OS readout from a pivotal partner trial, a generally supportive analyst consensus and favorable market conditions contributed to one of SMMT's largest single-session gains in recent months. The move highlights how sensitive the stock remains to new information on ivonescimab's clinical profile as the company approaches an important regulatory milestone.